US3714232A - 5-arylphenyl sulfonic acids - Google Patents

5-arylphenyl sulfonic acids Download PDF

Info

Publication number
US3714232A
US3714232A US00836610A US3714232DA US3714232A US 3714232 A US3714232 A US 3714232A US 00836610 A US00836610 A US 00836610A US 3714232D A US3714232D A US 3714232DA US 3714232 A US3714232 A US 3714232A
Authority
US
United States
Prior art keywords
sulfonic acid
fluorophenyl
isopropoxyphenyl
sulfonamide
acetoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00836610A
Inventor
L Sarett
J Hannah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of US3714232A publication Critical patent/US3714232A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms

Definitions

  • This invention is new S-aryl and heteroaryl phenyl sulfonic acid compounds and their derivatives, as well as the processes for preparing these compounds and their use as medicinal agents.
  • new S-aryl and heteroaryl-Z-hydroxyphenyl sulfonic acids and derivatives are the object of this invention.
  • the compounds of this invention contain a useful degree of anti-inflammatory activity and effectively prevent and inhibit edema and granuloma tissue formation. These compounds further contain a moderate degree of anti-pyretic and analgesic activity.
  • New -aryl and heteroaryl phenyl sulfonic acid compounds and their derivatives are described in this invention. More specifically, this invention describes new S-aryl and heteroaryl-Z-hydroxyphenyl sulfonic acid derivatives and further relates to the non-toxic pharmaceutically acceptable salts, esters and amides of the sulfonic acids, as well as the various ether derivatives. Included also in this invention are their methods of preparation and their treatment as medicinal agents.
  • the present invention embraces those compounds having the following structural formula I where Ar is any benzenoid or non-benzenoid aromatic-like structure (preferably phenyl, styryl, naphthyl, etc.) containing one or more R substituents which may be at any position on the ring (preferably at the 2, 4 and 6-positions), or a heteroaryl structure (preferably pyridyl or thienyl),
  • Ar is any benzenoid or non-benzenoid aromatic-like structure (preferably phenyl, styryl, naphthyl, etc.) containing one or more R substituents which may be at any position on the ring (preferably at the 2, 4 and 6-positions), or a heteroaryl structure (preferably pyridyl or thienyl),
  • R is hydrogen, alkyl (preferably lower alkyl such as methyl, ethyl, propyl, i-propyl, etc.), alkenyl (preferably lower alkenyl such as vinyl, allyl, etc.), halogen (preferably fluoro and chloro), haloalkyl (preferably haloloweralkyl such as trifluoromethyl), hydroxy, alkoxy (preferably lower alkoxy such as methoxy, ethoxy, etc.), nitro, amino, alkylamino (preferably lower alkylamino such as methylamino, ethylamino, etc.), dialkylamino (preferably dilower alkylamino such as dimethylamino, methylethylamino, etc.), alkylthio (preferably lower alkylthio such as methylthio, ethylthio, etc.), alkylsulfonyl (preferably lower alltylsulfonyl such as methylsulf
  • R is --0l-l
  • M in general is any base which will form an acid addition salt with a sulfonic acid and whose pharmacological properties will not cause an adverse physiological effect when ingested by the body system (preferably an alkali, alkaline earth or aluminum metal such as sodiurn, potassium, calcium, magnesium and aluminum metals),
  • R is alkyl (preferably lower alkyl such as methyl, ethyl, propyl, i-propyl, etc.), aryl (preferably mononuclear aryl such as phenyl, tolyl, xylyl, etc.), aralkyl (preferably arlower alkyl such as benzyl, phenethyl, etc.),
  • R, and R are hydrogen, alkyl (preferably lower alkyl such as methyl, ethyl, propyl, etc.), cycloalkyl (preferably cyclolower alkyl such as cyclopropyl, cyclobutyl, etc.), aryl (preferably phenyl), aralkyl (preferably arlower alkyl such as benzyl, phenethyl, etc.); R and K, may be the same or different and when taken together form a heterocyclic ring such as N-piperidino, N- morpholino, N-piperazino, N-homopiperazino, N-pyrrolidino, etc.; and R is hydrogen, alkyl (preferably lower alkyl such as methyl, ethyl, propyl, i-propyl, etc.), aralkyl (preferably arlower alkyl such as benzyl, phenethyl, etc.), or acyl (preferably lower acyl such
  • R is --OI-I
  • the compounds described in this invention have anti-inflammatory activity and are effective in the prevention and inhibition of edema and granuloma tissue formation.
  • they have a useful degree of anti-pyretic and analgesic activity.
  • they may be administered orally, topically, parenterally or rectally.
  • they may be administered in tablets or capsules, the optimum dosage depending on the particular compound being used and the type and severity of the condition being treated.
  • oral dose levels of preferred compounds in the range of 0.5-30 mg./kg. (preferably in the range of 3-15 mgJkg. per day) are useful in con trol of arthritic conditions, depending on the activity of the specific compound and the reaction sensitivity of the patient.
  • Comparable dosages may be used when the administration is topically, parenterally or rectally.
  • S-aryl or heteroaryl-Z-hydrophenyl sulfonic acid compounds and derivatives of this invention are prepared by the following methods.
  • SulfonatiOn of a 4-'aryl or heteroaryl phenol or its ether derivatives readily takes place at the ortho position using mild sulfonating conditions.
  • One such suitable method istreatment with concentrated sulfuric acid at mild temperatures (preferably 15-50C.).
  • the alkoxy or aralkoxy groups may then be hydrolyzed back to the phenol by known methods such as with the use of boron trihalide, boron trichloride or trifluoride. It is preferred that the sulfonation take place on the isopropoxy derivative which is then easily hydrolyzed using mild conditions.
  • the 5-aryl or heteroaryl-Z-hydroxyphenylsulfonic acid may then be acylated to prepare the desired S-aryl or heteroaryl-Z-acyloxyphenylsulfonic acids.
  • One such method is by acylation with a suitable anhydride such as acetic anhydride in an aqueous alkaline solution to obtain 5-aryl or heteroaryl-2-acetoxyphenylsulfonic acids.
  • Kr and R are as described above; Y is hydrogen, alkyl or aralkyl; and Z is acyl.
  • the sulfonic acid esters are conveniently prepared by reacting S-aryl or heteroaryl-Z-alkoxyphenyl sulfonyl halide with the proper alcohol of the formula R'OH. lt is preferred to carry out this esterification in a basic medium such as anhydrous alcoholic alkaline or amine solution.
  • a basic medium such as anhydrous alcoholic alkaline or amine solution.
  • Direct halosulfonation is readily carried out with chloro or fluoro-sulfonic acid on the 4-aryl or heteroaryl phenyl alkyl ethers. This may be carried out in an organic solvent such as chloroform or carbon tetrachloride and at mild temperatures (preferably at 5 30C.).
  • the 5-aryl or heteroaryl-Z-alkoxyphenyl sulfonyl halide can then be treated with ammonia or with various substituted amines of the formula a HN to give the desired sulfonamide.
  • the alkoxy group can be hydrolyzed back to the phenol by known methods (such as with boron trichloride or trifluoride) and then acylated (such as with a suitable anhydride) to the desired S-aryl or heteroaryl-Z-acyloxyphenyl sulfonamides.
  • known methods such as with boron trichloride or trifluoride
  • acylated such as with a suitable anhydride
  • one R substituent may be converted to another desired substituent by conven- I tional method.
  • the 4-aryl and heteroaryl phenol starting materials of this invention are either known compounds or can be prepared by the following procedure. Reduction of know n Z-a ryTand heteroa ryl niti'obenzene carnp ounds to the corresponding aniline is carried out by conven- 35 tional methods. This is then diazotized to the desired phenol, which can then be alkylated or acylated by known methods. A detailed description of this preparation follows.
  • EXAMPLE 2 l-(p-fluorophenyl)isopropoxy benzene 4-Fluoro-4-hydroxybiphenyl (0.1 mole) is added to a solution of sodium hydroxide (0.11 mole) in isopropanol (100 1111.), heated to reflux, and treated dropwise with isopropyl iodide (0.1 mole). The completed mixture is stirred and boiled under reflux for 2 hours, evaporated to dryness, dissolved in benzene, washed with water, and the benzene evaporated. The residual solid is then crystallized from ethanolethyl acetate to obtain 4-(p-fluorophenyl)isopropoxy benzene.
  • the product obtained is 4-(pnitrophenyl)isopropoxybenzene.
  • EXAMPLE 4a 4'FluOm-Lhydmxybiphenyl 8 g. is 58138" to sul furic acid (25 ml., density 1.84) at 20. The mixture is stirred at 40 for 20 minutes then poured into ice.
  • Example 4 When an equimolar amountof the compounds of Table I, Example 4, are used in place of 4-(pfluorophenyl)-2-hydroxyphenyl sulfonic acid, the corresponding product of Table 1 below is prepared.
  • EXAMPLE 7 S-(p-Fluorophenyl)-2-isopropoxyphenyl sulfonamide 5-(p-Fluorophenyl)-2-isopropoxyphenyl sulfonyl chloride (2 g.) is vigorously shaken with an excess of concentrated aqueous ammonia (10 ml.) at room temperature for 5 minutes. The mixture is diluted with water (10 ml.) and 5-(p-fluorophenyl)-2-isopropoxyphenyl sulfonamide is filtered off, washed with water, and recrystallized from aqueous ethanol.
  • the solution is rapidly heated to reflux for 2 minutes, and cooled at once to room temperature.
  • the mixture is evaporated to dryness at 20/0.l, mm. pressure, and the residual S-(pfluorophenyl)-2-hydroxyphenyl sulfonamide recrystallized from aqueous ethanol.
  • Ethyl S-(p-aminophenyD-Z-methoxyphenyl sulfonate A mixture of pure ethyl S-(p-nitrophenyl)-2-methoxyphenyl sulfonate (0.01 mole) in methanol-dioxane (1:1) (ca. 200 ml.) is reacted with hydrogen at room temperature (40 p.s.i.) in the presence of 10% ld/C (1.0 g.).
  • Ethyl 5-(p-hydroxyphenyl)-2-methoxyphenyl sulfonate A mixture of ethyl 5-(p-aminophenyl)-2-methoxyphenyl sulfonate (0.2 moles), water (600 ml.) and concentrated sulfuric acid (25 ml.) is'cooled to 10C. and a solution of sodium nitrite (0.21 mole) in a minimum of water is added gradually. When the presence of free nitrous acid is detected (starch-iodide paper), the addition is stopped and thediazotization mixture is allowed to warm to room temperature, then heated on a steam-bath until there is no more nitrogen evolution.
  • Methyl S-(p-methylthiophenyl)-2-isopropoxyphenyl sulfonate A mixture of methyl 2-(p-mercaptophenyl)-2- isopropoxyphenyl sulfonate (0.01 moles) in a deaerated aqueous KOH solution (0.01 mole) is treated with dimethylsulfate (0.012 mole) at room temperature over 1 hour, the mixture acidified, extracted well with ether, and the dried ether extracts chromatographed on a silica gel column using an ether-petroleum ether system (v/v O-30 percent ether) as eluant yielding methyl S-(p-methylthiophenyl) -2-isopropoxyphenyl sulfonate.
  • Methyl 5-(p-methylsulfinylphenyl)-2- isopropoxyphenyl sulfonate To an ice-cooled solution of methyl S-(p-methylthiophenyl)-2-isopropoxyphenyl sulfonate (0.01 mole) in methanol-acetone is added a solution of sodium metaperiodate (0.01 mole) in a minimum of water, and the mixture stirred at 0-8% C. until precipitation of sodium iodate is completed. The iodate is removed by filtration, the solvents removed in vacuo, and the Ar is phenyl containing one or more R substituents residue taken up in chloroform and ether.
  • the com which may be at any position on the ring; bined organic extracts are dried, filtered and concen- R is halogen, trifluoromethyl, hydroxy, lower alkoxy, trated.
  • Purification of the methyl S-(p-methylsulfinitro, amino, di(lower alkyl)amino, mercapto,- nylphenyl)-2-isopropoxyphenyl sulfonate is affected lower alkylthio, l0W6! alkylsulfinyl; via recrystallization or chromatography (silica gel) of 1 is M Where M is an alkali, alkaline its methyl ester. earth or aluminum metal; and
  • R is hydrogen, or lower alkanoyl.
  • a compound of the formula 2. A compound according to claim 1 where Ar is phenyl, R is halo, R, is --OH; or --OM; and R is hydrogen or lower alkanoyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

5-Aryl and heteroarylphenyl sulfonic acids and their derivatives are described and the processes for preparing the same are disclosed. These compounds exhibit anti-inflammatory properties and also possess an effective degree of anti-pyretic and analgesic activity.

Description

6 United States Patent 1 3,714,232 Sarett et al. Jan. 30, 1973 [54] S-ARYLPHENYL SULFONIC ACHDS [58] Field oi Search ..260/479 R, 512 R, 448 R [75] Inventors: Lewis B. Sarett, Princeton; John P Hannah, Matawan, both of NJ. i561 Remremes cued [73] Assignee: Merck & Co., Inc., Rahway, NJ. UNITED STATES PATENTS [22] Filed: June 25, 1969 2,323,334 3/1958 De Groote ..260/512 [21] Appl. No.: 836,610
Primary Examiner-James A. Patten Att0rneyMichael C. Sudol, Jr., Harry E. Westlake, [52] U.S. Cl. ..260/479 R, 260/141, 260/239 B, In and L Louis wolk 260/239 BF, 260/247.1, 260/268 S, 260/293.65, 260/294.8 B, 260/297 R, 260/326, 260/332.5, 260/332.2 R, 260/332.3 [57] ABSTRACT R, 260/430, 260/448 R, 260/456 A, 260/456 S-Aryl and heteroarylphenyl sulfonic acids and their 26O/512 260/543 260/556 derivatives are described and the processes for prepar- 260/556 26O/575, 260/62O, ing the same are disclosed. These compounds exhibit 124/244, 1 124/250, 424/267 anti-inflammatory properties and also possess an ef- 424/274 424/275, 124/311, 124/321, fective degree of anti-pyretic and analgesic activity. 424/325, 424/341 [51] Int. Cl. ..C07c 143/44, C07c 147/06 4 Claims, N0 Drawings S-ARYLPHENYL SULFONIC ACIDS BACKGROUND OF THE INVENTION There has been much emphasis during the past two decades to synthesize anti-inflammatory compounds. Many of those agents developed have been highly effective steroids, but are complex in structure. The most desirable anti-inflammatory agent should be relatively active and simple in structure.
SUMMARY OF THE INVENTION This invention is new S-aryl and heteroaryl phenyl sulfonic acid compounds and their derivatives, as well as the processes for preparing these compounds and their use as medicinal agents. In particular, new S-aryl and heteroaryl-Z-hydroxyphenyl sulfonic acids and derivatives are the object of this invention. We have found that the compounds of this invention contain a useful degree of anti-inflammatory activity and effectively prevent and inhibit edema and granuloma tissue formation. These compounds further contain a moderate degree of anti-pyretic and analgesic activity.
DESCRIPTION OF THE PREFERRED EMBODIMENTS New -aryl and heteroaryl phenyl sulfonic acid compounds and their derivatives are described in this invention. More specifically, this invention describes new S-aryl and heteroaryl-Z-hydroxyphenyl sulfonic acid derivatives and further relates to the non-toxic pharmaceutically acceptable salts, esters and amides of the sulfonic acids, as well as the various ether derivatives. Included also in this invention are their methods of preparation and their treatment as medicinal agents.
In a more narrow aspect, the present invention embraces those compounds having the following structural formula I where Ar is any benzenoid or non-benzenoid aromatic-like structure (preferably phenyl, styryl, naphthyl, etc.) containing one or more R substituents which may be at any position on the ring (preferably at the 2, 4 and 6-positions), or a heteroaryl structure (preferably pyridyl or thienyl),
R is hydrogen, alkyl (preferably lower alkyl such as methyl, ethyl, propyl, i-propyl, etc.), alkenyl (preferably lower alkenyl such as vinyl, allyl, etc.), halogen (preferably fluoro and chloro), haloalkyl (preferably haloloweralkyl such as trifluoromethyl), hydroxy, alkoxy (preferably lower alkoxy such as methoxy, ethoxy, etc.), nitro, amino, alkylamino (preferably lower alkylamino such as methylamino, ethylamino, etc.), dialkylamino (preferably dilower alkylamino such as dimethylamino, methylethylamino, etc.), alkylthio (preferably lower alkylthio such as methylthio, ethylthio, etc.), alkylsulfonyl (preferably lower alltylsulfonyl such as methylsulfonyl), alkylsulfenyl (preferably lower alkylsulfenyl such as methylsulfenyl) and sulfamyl;
R, is --0l-l,
0M where M in general is any base which will form an acid addition salt with a sulfonic acid and whose pharmacological properties will not cause an adverse physiological effect when ingested by the body system (preferably an alkali, alkaline earth or aluminum metal such as sodiurn, potassium, calcium, magnesium and aluminum metals),
--()R where R is alkyl (preferably lower alkyl such as methyl, ethyl, propyl, i-propyl, etc.), aryl (preferably mononuclear aryl such as phenyl, tolyl, xylyl, etc.), aralkyl (preferably arlower alkyl such as benzyl, phenethyl, etc.),
where R, and R are hydrogen, alkyl (preferably lower alkyl such as methyl, ethyl, propyl, etc.), cycloalkyl (preferably cyclolower alkyl such as cyclopropyl, cyclobutyl, etc.), aryl (preferably phenyl), aralkyl (preferably arlower alkyl such as benzyl, phenethyl, etc.); R and K, may be the same or different and when taken together form a heterocyclic ring such as N-piperidino, N- morpholino, N-piperazino, N-homopiperazino, N-pyrrolidino, etc.; and R is hydrogen, alkyl (preferably lower alkyl such as methyl, ethyl, propyl, i-propyl, etc.), aralkyl (preferably arlower alkyl such as benzyl, phenethyl, etc.), or acyl (preferably lower acyl such as formyl, acetyl, propionyl, butyryl, etc.). The more preferred compounds of this invention embrace those compounds of the structural formula I where Ar is phenyl or 4-pyridyl; R is halo, diloweralkylamino or loweralkoxy;
R is --OI-I,
OM, OR' where R is lower alkyl, -NI'I where R and R are lower alkyl; and R, is hydrogen or acetyl. Representative compounds of this invention are as follows:
2-hydroxy-5-(p-fluorophenyl)phenyl sulfonic acid 2-acetoxy-5-(p-fluorophenyl)phenyl sulfonic acid Z-hydroxy-S-(p-methoxyphenyl)phenyl sulfonamide 2-methoxy-S-(p-nitrophenyl)phenyl N,N-dimethyl sulfonamide sodio 2-acetoxy-5-(p-chlorophenyl)phenyl sulfonic acid 2-isopropoxy-5-(p-dimethylaminophenyl)phenyl-N- benzyl sulfonamide 2-methoxy-5-(p-nitrophenyl)phenyl sulfonic acid 2-acetoxy-5-(4 -pyridyl)phenyl sulfonic acid Various tests in animals are carried out to show the ability of compounds to exhibit reactions that can be correlated with anti-inflammatory activity in humans. One such test used is the Carrageenin testing method, which is known to correlate well with anti-inflammatory activity in humans and is a standard test used to determine anti-inflammatory activities. This outlined in detail by C. A. Winter, Proc. Soc. Exptl. Biolog. & Med., 1962, III, 544. This test shows the correlation 1 between clinically active compounds such as lndocin, Aspirin, Butazolidin, Tandearil, Cortone, Hydrocortone,d! Decadron and those of unknown activity. In view of results from tests such as this, the compounds of this invention can be considered to be active 20 anti-inflammatory agents.
We have found that the compounds described in this invention have anti-inflammatory activity and are effective in the prevention and inhibition of edema and granuloma tissue formation. In addition, they have a useful degree of anti-pyretic and analgesic activity. For these purposes, they may be administered orally, topically, parenterally or rectally. Orally, they may be administered in tablets or capsules, the optimum dosage depending on the particular compound being used and the type and severity of the condition being treated. Although the optimum quantities to be used will dependon the compound employed and the particular type of disease treated, oral dose levels of preferred compounds in the range of 0.5-30 mg./kg. (preferably in the range of 3-15 mgJkg. per day) are useful in con trol of arthritic conditions, depending on the activity of the specific compound and the reaction sensitivity of the patient. Comparable dosages may be used when the administration is topically, parenterally or rectally.
The S-aryl or heteroaryl-Z-hydrophenyl sulfonic acid compounds and derivatives of this invention are prepared by the following methods.
SulfonatiOn of a 4-'aryl or heteroaryl phenol or its ether derivatives readily takes place at the ortho position using mild sulfonating conditions. One such suitable method istreatment with concentrated sulfuric acid at mild temperatures (preferably 15-50C.). The alkoxy or aralkoxy groups may then be hydrolyzed back to the phenol by known methods such as with the use of boron trihalide, boron trichloride or trifluoride. It is preferred that the sulfonation take place on the isopropoxy derivative which is then easily hydrolyzed using mild conditions.
The 5-aryl or heteroaryl-Z-hydroxyphenylsulfonic acid may then be acylated to prepare the desired S-aryl or heteroaryl-Z-acyloxyphenylsulfonic acids. One such method is by acylation with a suitable anhydride such as acetic anhydride in an aqueous alkaline solution to obtain 5-aryl or heteroaryl-2-acetoxyphenylsulfonic acids. These reactions may be illustrated by the following equations:
LII
where Kr and R are as described above; Y is hydrogen, alkyl or aralkyl; and Z is acyl.
The sulfonic acid esters are conveniently prepared by reacting S-aryl or heteroaryl-Z-alkoxyphenyl sulfonyl halide with the proper alcohol of the formula R'OH. lt is preferred to carry out this esterification in a basic medium such as anhydrous alcoholic alkaline or amine solution. The following equations illustrate these reactions:
sti)? R-Em} O OY $0203 REA1'] Q -OY some l sogon' where Ar, R and OR are as described above; Y is alkyl or aralkyl, Z is acyl; and X is halogen.
Direct halosulfonation is readily carried out with chloro or fluoro-sulfonic acid on the 4-aryl or heteroaryl phenyl alkyl ethers. This may be carried out in an organic solvent such as chloroform or carbon tetrachloride and at mild temperatures (preferably at 5 30C.). The 5-aryl or heteroaryl-Z-alkoxyphenyl sulfonyl halide can then be treated with ammonia or with various substituted amines of the formula a HN to give the desired sulfonamide. If desired, the alkoxy group can be hydrolyzed back to the phenol by known methods (such as with boron trichloride or trifluoride) and then acylated (such as with a suitable anhydride) to the desired S-aryl or heteroaryl-Z-acyloxyphenyl sulfonamides. The following equations illustrate these reactions:
SO2N R Ar where Ar, R, R and R are as described above; Y is alkyl or aralkyl; Z is acyl; and X is halogen.
At various stages of synthesis one R substituent may be converted to another desired substituent by conven- I tional method.
The 4-aryl and heteroaryl phenol starting materials of this invention are either known compounds or can be prepared by the following procedure. Reduction of know n Z-a ryTand heteroa ryl niti'obenzene carnp ounds to the corresponding aniline is carried out by conven- 35 tional methods. This is then diazotized to the desired phenol, which can then be alkylated or acylated by known methods. A detailed description of this preparation follows.
EXAMPLE 1 4-(p-fluorophenyl)aniline To 10.9 g. of 4-(p-fluorophenyl)nitrobenzene in 350 ml. of ethanol is added 1.5 g. of platinum oxide and this; is reduced over hydrogen. The reaction mixture is then filtered through a pad of filter cel and evaporated in vacuo to yield 4-(p-fluorophenyl)aniline.
4-(p-fluorophenyl)phenol A solution of 32.66 grams of 4-(p-fluorophenyl)- 5 aniline in 120 ml. of glacial acetic acid is cooled to 10-20C. To this solution is added slowly a solution of 12.25 grams of sodium nitrite in 120 ml. of water with stirring and continued cooling. Five minutes after this addition, the suspension of the diazonium acetate is added slowly to a boiling solution of ml. of concentrated sulfuric acid and 200 ml. of water. After the final addition of the diazonium salt, the suspension is boiled for an additional 5 minutes and then allowed to cool to room temperature. The reaction mixture is then fil- 0 tered and the cake dried in vacuo to yield 4-(pfluorophenyl)-phenol (m.p. l52l61C.).
When the compounds of Table I below are substituted for 4-(p-fluorophenyl)nitrobenzene in the. above example, the corresponding phenol of Table II'65 below is prepared.
TABLE I 4-(p-chlorophenyl)nitrobenzene 4-(2,6-dichlorophenyl)nitrobenzene 4-(p-bromophenyl)nitrobenzene 4-(o-rnethylphenyl)nitrobenzene 4-(3,4,5-trimethylphenyl)nitrobenzene 4-(p-methoxyphenyDnitrobenzene 4-(p-dimethylaminophenyl)nitrobenzene 4(p-trifluoromethylphenyl)nitrobenzene 4-(p-mercaptophenyl)nitrobenzene 4-(a-naphthyl)nitrobenzene 4-( styryl )nitrobenzene 4-(2-pyridyl)nitrobenzene 4-(3-pyridyl)nitrobenzene 4-(4-pyridyl)nitrobenzene 4-(2-thienyl)nitrobenzene 4-(3-thienyl)nitrobenzene TABLE II 4-(p-chlorophenyl)phenol 4-(2,6-dichlorophenyl)phenol 4-(p-bromophenyl)phenol 4-(o-methylphenyl)phenol 4-(3,4,5-trimethylphenyl)phenol 4-(p-methoxyphenyl)phenol 4-(p-dimethylaminophenyl)phenol 4-(p-trifluoromethylphenyl)phenol -(p-mercaptophenyl)phenol 4-(cz-naphthyl)phenol 4-(styryl)phenol 4-(2-pyridyl)phenol 4-( 3-pyridyl)phenol 4-(4-pyridyl)phenol 4-(2-thienyl)phenol 4'(3-thienyl)phenol The ether derivatives may then be prepared by conventional methods using the suitable alkyl or aralkyl reagent, or the acyl derivatives may be directly made using conventional acylating reagents.
The following are detailed examples which show the preparation of the various compounds described in this invention. They are to be construed as illustrations of said compounds and not as limitations thereof.
EXAMPLE 2 l-(p-fluorophenyl)isopropoxy benzene 4-Fluoro-4-hydroxybiphenyl (0.1 mole) is added to a solution of sodium hydroxide (0.11 mole) in isopropanol (100 1111.), heated to reflux, and treated dropwise with isopropyl iodide (0.1 mole). The completed mixture is stirred and boiled under reflux for 2 hours, evaporated to dryness, dissolved in benzene, washed with water, and the benzene evaporated. The residual solid is then crystallized from ethanolethyl acetate to obtain 4-(p-fluorophenyl)isopropoxy benzene.
When an equimolar amount of 440 -nitro-4-hydroxybiphenyl is used in place of 4-fluoro-4-hydroxybiphen y] in the above example, the product obtained is 4-(pnitrophenyl)isopropoxybenzene.
When an equimolar amount of the 4-arylphenol compounds of Table II, Example I, are used in place of 4'-fluoro-4-hydroxybiphenyl in the above example, the corresponding compound of Table I below is prepared.
TABLE I 4-(p-chlorophenyl)isopropoxybenzene 4-( 2 ,6-dichlorophenyl )isopropoxybenzene 4-(p-bromophenyl)isopropoxybenzene o-methylphenyl)isopropoxybenzene 3,4,5-trimethylphenyl)isopropoxybenzene 4-( p-methoxyphenyl )isopropoxyben zene 4-( p-dimethylaminophenyl )isopropoxybenzene 4-( p-trifluoromethylphenyl)isopropoxybenzene 4-(a-naphthyl )isopropoxybenzene 4-( styryl )isopropoxybenzene 4-( 2-pyridyl )isopropoxybenzene 4-( 3-pyridyl )isopropoxybenzene 4-( 4-pyridyl )isopropoxybenzene 4-( Z-thienyl )isopropoxybenzene 4-( 3-thienyl )isopropoxybenzene When methyl iodide, ethylbromide, t-butyliodide and benzyl bromide are used in place of isopropyl iodide in the above example with the appropriate solvent, the corresponding ether products are obtained. A
representative list of these compounds is shown in Table II below.
TABLE II (p-fluorophenyl )methoxybenzene 4- 4-(p-fluorophenyl)t-butoxybenzene 4- (p-fluorophenyl)benzyloxybenzene 4-(p-chlorophenyl)methoxybenzene 4-(o-methylphenyl)ethoxybenzene 4-(p-methoxyphenyl)methoxybenzene 4-(p-trifluoromethylphenyl)methoxybenzene 4-(qz naphthyl)ethoxybenzene i s tyryl-benzyloxybenzene 4-(p-nitrophenyl)methoxybenzene 4-(p-nitrophenyl)benzyloxybenzene 4-(3-pyridyl)methoxybenzene 4-(4-pyridyl)benzyloxybenzene 4-(2-thienyl)ethoxybenzene EXAMPLE 3 S-(p-fluorophenyl)-2-isopropoxyphenyl sulfonic acid 4-Fluoro-4-isopropoxybiphenyl (8.0 g.) is added to sulfuric acid ml., density 1.84) at 20. The mixture is then heated to 80 with stirring in 10 minutes,.held at I this temperature for 10 minutes, and poured onto ice.
The precipitate of 4-(p-fluorophenyl)-2-isopropox- 40 yphenylsulfonic acid is filtered off, washed with water, and dried in vacuo.
When an equimolar amount of the 4-aryl and heteroaryl phenyl ethers of Example 2 are used in place of 47-fluoro-4-isopropoxybiphenyl in the above example, the corresponding sulfonic acid of Table 1 below is prepared.
TABLE I S-(p-nitrophenyl)-2-isopropoxyphenyl sulfonic acid 50 S-(p-chlorophenyl)-2-isopropoxyphenyl sulfonic acid 5-(2,6-dichloroph,enyl)-2-isopropoxyphenyl sulfonic acid 5-(p-bromophenyl)-2-isopropoxyphenyl sulfonic acid 5-(o-methylphenyl)-2-isopropoxyphenyl sulfonic acid 5-(3,4,5-trimethylphenyl)-2-isopropoxyphenyl sul- 6 fonic acid S-(p-methoxyphenyl)-2-isopropoxyphenyl sulfonic acid S-(p-dimethylaminophenyl)-2-isopropoxyphenyl sulfonic acid 5-(p-trifluoromethylphenyl)-2-isopropoxyphenyl sulfonic acid S-(a-naphthyl)-2-isopropoxyphenyl sulfonic acid 5-styryl-2-isopropoxyphenyl sulfonic acid S-(Z-pyridyl)-2-isopropoxyphenyl sulfonic acid 5-(3-pyridyl)-2-isopropoxyphenyl sulfonic acid 5-(4-pyridyl)-2-isopropoxyphenyl sulfonic acid 5-(Z-thienyl)-2-isopropoxyphenyl sulfonic acid 5-(3-thienyl)-2-isopropoxyphenyl sulfonic acid 5(p-fluorophenyl)-2-methoxyphenyl sulfonic acid S-(p-fluorophenyl)-2-t-butoxyphenyl sulfonic acid S-(p-fluorophenyl)-2-benzyloxyphenyl sulfonic acid S-(p-chlorophenyl)-2-methoxyphenyl sulfonic acid S-(o-methylphenyl)-2-ethoxyphenyl sulfonic acid S-(p-methoxyphenyl)-2-methoxyphenyl acid 5-(p-trifluoromethylphenyl)-2-methoxyphenyl sulfonic acid S-(a-naphthyl)-2-ethoxyphenyl sulfonic acid S-styryl-Z-benzyloxyphenyl sulfonic acid S-(p-nitrophenyl)-2-methoxyphenyl sulfonic acid 5-(p-nitrophenyl)-2-benzyloxyphenyl sulfonic acid 5-(3-pyridyl)-2-methoxyphenyl sulfonic acid 5-(4-pyridyl)-2-benzyloxyphenyl sulfonic acid 5-(2-thienyl)-2-ethoxyphenyl sulfonic acid.
EXAMPLE4 S-(p-fluorophenyl)-2-hydroxyphenyl sulfonic acid S-(p-fluorophenyl)-2-isopropoxyphenyl sulfonic acid (5.0 g.) is dissolved in hot aqueous 48 percent hydrobromic acid (25 ml.) and the solution heated to reflux for a few minutes, and then cooled to room temperature. Themixture is evaporated to dryness at -40l0.i mm pressure, and the residue crystallized from aqueous ethanol to yield 4-(p-fluorophenyl)-2- hydroxyphenyl sulfonic acid.
When an equimolar amount of the compounds of Table 1, Example 3, are used in place of 5-(p-' fluorophenyl)-2-isopropoxyphenyl sulfonic acid in the above example, the corresponding product of Table I below is prepared.
EXAMPLE 4a 4'FluOm-Lhydmxybiphenyl 8 g.) is 58138" to sul furic acid (25 ml., density 1.84) at 20. The mixture is stirred at 40 for 20 minutes then poured into ice.
Precipitated 5-(p-fluorophenyl)-2-hydroxyphenyl sulfonic acid is filtered off, washed with a little water, and dried in vacuo.
When an equimolar amount of the 4-aryl or heteroaryl phenol compounds of Table II, Example 1,
sulfonic -(p-Fluorophenyl)-2-acetoxybenzene sulfonic acid A mixture of 5-(p-flu0rophenyl)-2-hydroxyphenyl' sulfonic acid (2 g.), acetic anhydride (4 ml.), and phosphoric acid (0.2 ml.) is heated to 100 for minutes. The mixture is cooled to 80 and water (2 ml.) is added in one portion down the condenser, vigorously decomposing the excess acetic anhydride. More water (10 ml.) is added and the mixture cooled to 0. Precipitated 5-(p-fluorophenyl)-2-acetoxyphenyl sulfonic acid is filtered off, and recrystallized from an anhydrous benzene-cyclohexane mixture.
When an equimolar amountof the compounds of Table I, Example 4, are used in place of 4-(pfluorophenyl)-2-hydroxyphenyl sulfonic acid, the corresponding product of Table 1 below is prepared.
TABLE I 5-(p-nitrophenyl)-2-acetoxyphenyl sulfonic acid 5-(p-chlorophenyl)w2-acetoxyphenyl sulfonic acid 5-(2,6-dichlorophenyl)-2-acetoxyphenyl sulfonic acid 5-(p-bromophenyl)-2-acetoxyphenyl sulfonic acid 5-(o-methylphenyl)-2-acetoxyphenyl sulfonic acid 5-(3,4,5-trimethylphenyl)-2-acetoxyphenyl sulfonic acid S-(p-methoxyphenyl)-2-acetoxyphenyl sulfonic acid 5-(p-dimethylaminophenyl)-2-acetoxyphenyl sulfonic acid I 5-(p-trifluoromethylphenyl)-2-acetoxyphenyl sulfonic acid S-(a-naphthyl)-2-acetoxyphenyl sulfonic acid 5 -(styryl)-2-acetoxyphenyl sulfonic acid 5-( Z-pyridyl)-2-acetoxyphenyl sulfonic acid 5-(S-pyridyl)-2-acetoxyphenyl sulfonic acid 5-(4-pyridyl)-2-acetoxyphenyl sulfonic acid 5-(2-thienyl)-2-acetoxyphenylsulfonic acid 5-(3-thienyl)-2-acetoxyphenyl sulfonic acid When an equimolar amount of propionic anhydride, butyric anhydride, or crotonoic anhydride are used in place of acetic anhydride in the above example, thecorresponding 5-aryl or heteroaryl-2-propionyloxy, 2- butyryloxy and 2-crotonyloxyphenyl sulfonic acid is prepared. A representative list of these compounds is shown below in Table II.
TABLE I1 S-(p-fluorophenyl)-2-propionyloxyphenyl sulfonic acid 5-(p-nitrophenyl)-2-propionyloxyphenyl sulfonic acid sulfonic ybiphenyl (0.1 mole) in carbon tetrachloride (200 ml.) at a rate which does not allow the internal temperature to rise above 25 (cool if necessary). The mixture on completion is stirred for an additional 2 hours at room 5 temperature, then stirred vigorously with crushed ice g.) for 1 minute. The carbon tetrachloride layer is quickly separated, washed once with dilute aqueous sodium carbonate, dried for a few minutes over magnesium sulfate, filtered, and evaporated in vacuo, leaving 5-(p-fluorophenyl)-2-isopropoxyphenyl sulfonyl chloride of sufficient purity to be used directly in the following examples (7 & l0).
When the compounds of Example 2 are used in place of 4-fluoro-4-isopropoxybiphenyl in the above example, the corresponding chlorosulfonated product is prepared.
EXAMPLE 7 S-(p-Fluorophenyl)-2-isopropoxyphenyl sulfonamide 5-(p-Fluorophenyl)-2-isopropoxyphenyl sulfonyl chloride (2 g.) is vigorously shaken with an excess of concentrated aqueous ammonia (10 ml.) at room temperature for 5 minutes. The mixture is diluted with water (10 ml.) and 5-(p-fluorophenyl)-2-isopropoxyphenyl sulfonamide is filtered off, washed with water, and recrystallized from aqueous ethanol.
When the sulfonyl chloride compounds of Example 6 are used inplace of 5-(p-fluorophenyl)-2-isopropoxyphenyl sulfonyl chloride in the above example, the corresponding sulfonamides are prepared.
When methylamine, dimethylamine, cyclopropylamine, cyclohexylamine, aniline, benzylamine, piperidine, morpholine, piperazine, homopiperazine or pyrrolidine are used in place of ammonia in the above example, the corresponding sulfonamides are prepared. A representative list is shown below.
N-methyl S-(p-fluorophenyl)-2-isopropoxyphenyl sulfonamide N,N-dimethyl sulfonamide N-cyclopropyl 5-(p-chlorophenyl)-2-isopropoxyphenyl sulfonamide N-phenyl 5-(o-methylphenyl')-2-ethoxyphenyl sulfonamide N,N-diphenyl 5-(p-methoxyphenyl-2-isopropox yphenyl sulfonamide N-be'nzyl 5-(p-dimethylaminophenyl)-2-isopropox- 5 -(p-nitrophenyl )-2-methoxyphenyl yphenyl sulfonamide N-piper idino S-(a-naphthyl)-2-ethoxyphenyl sulfonamide N-morpholino 5-styryl-2-benzyloxyphenyl sulfonamide N-piperazino 5-(p-fluorophenyl)-2-t-butoxyphenyl sulfonamide N-homopiperazino 5-(p-trifluoromethylphenyl)-2- isopropoxyphenyl sulfonamide N-pyrrolidino 5-(p-fluorophenyl)-2-benzyloxyphenyl sulfonamide N,N-dimethyl 5-(4-pyridyl)-2-isopropoxyphenyl sulfonamide N-piperazino 5-(S-pyridyl)-2-methoxyphenyl sulfonamide N,N-dicyclohexyl 5-(2-thienyl)-2 isopropoxyphenyl sulfonamide EXAMPLE 8 5-(p-Fluorophenyl)-2-hydroxyphenyl sulfonamide 5{pfiuorophenyl)-2 isopropoxyphenyl sulfonamide (2 g.) is dissolved in hot aqueous 48 percent hydrobromic acid (20 ml.). The solution is rapidly heated to reflux for 2 minutes, and cooled at once to room temperature. The mixture is evaporated to dryness at 20/0.l, mm. pressure, and the residual S-(pfluorophenyl)-2-hydroxyphenyl sulfonamide recrystallized from aqueous ethanol.
When the sulionamides' of Example? 12?; area? th e above example in place of 5-(p-fluorophenyl)-2- l isopropoxyphenyl sulfonamide, product below is prepared.
N-methyl-S-(p-fluorophenyl)-2-hydroxyphenyl sulfonamide N,N-dimethyl sulfonamide the corresponding -(p-nitrophenyl)-2-hydroxyphenyl N-cyclopropyl 5-(p-chlorophenyl)-2-hydroxyphenyl sulfonamide N-phenyl 5-(o-methylphenyl)-2-hydroxyphenyl sulsul- 5-(2-thienyl)-2-hydroxyphenyl EYKMFEE? 5 (p-Fluorophenyl)-2-acetoxyphenyl ifiEJrEiiiii' A mixture of S-(p-fluorophenyl)-2-hydroxyphenyl sulfonamide (2 g.), acetic anhydride (4 ml.) and phosphoric acid (0.2 ml.) is heated to 100 for minutesJThe mixture is cooled to 80 and water (2 ml.) added in one portion down the condenser. When the excess of acetic anhydride has decomposed more water (10 ml.) is added and the mixture cooled to 0. Precipitated 5-(p-fluorophenyl)-2-acetoxyphenyl sulfonamide is filtered off, and is recrystallized from an anhydrous benzene-cyclohexane mixture.
When the sulfonamides of Example 8 are used in place of .S-(p-fluorophenyl)-2-hydroxyphenyl sulfonamide in the above example, the corresponding product below is prepared.
N-methyl S-(p-fluoroph'enyl)-2-acetoxyphenyl sulfonamide N,N-dimethyl S-(p-nitrophenyl)-2-acetoxyphenyl sulfonamide N-cyclopropyl 5-(p-chlorophenyl)-2-acetoxyphenyl sulfonamide N-phenyl 5-(o-methylphenyl)-2-acetoxyphenyl sulfonamide N,N-diphenyl S-(p-methoxyphenyl)-2-acetoxyphenyl sulfonamide N-benzyl 5 (p-dimethylaminophenyl)-2-acetoxyphenyl sulfonamide N-piperidino 5-(a-naphthyl)-2-acetoxyphenyl sulfonamide N-morpholino '5-styryl-2-acetoxyphenyl sulfonamide N-piperazino 5-(p-fluorophenyl)-2-acetoxyphenyl sulfonamide I N-homopiperazino 5-(p-trifluoromethylphenyl)-2- acetoxyphenyl sulfonamide N-pyrrolidino 5-(p-fluorophenyl)-2-acetoxyphenyl sulfonamide N,N-dimethyl fonamide N-piperazino 5-(3-pyridyl)-2-acetoxyphenyl sulfonamide N,N-dicyclohexyl 5-(2-thienyl)-2-acetoxyphenyl sulfonamide When propionic anhydride, butyric anhydride and crotonic anhydride are used in place of acetic anhydride the corresponding product is prepared.
EXAMPLE l0 Methyl 5-(p-fluorophenyl)-2-isopropoxyphenyl sulfonate 5-(p-Fluorophenyl)-2-isopropoxyphenyl sulfonyl chloride (0.01 mole) is added in one portion to a solution of sodium methoxide (0.01 mole) in methanol (20 ml.) at room temperature. The mixture is stirred at room temperature for minutes then evaporated to 5-(4-pyridyl)-2-acetoxyphenyl suldryness in vacuo. The product is extracted from contaminating sodium chloride with anhydrous benzene. Evaporation of the benzene in vacuo leaves 5-(pfluorophenyl)-2-isopropoxyphenyl sulfonicacid methyl ester.
When the compounds of Example 6 are used in place of 5-(p-fluorophenyl)-2-isopropoxyphenyl sulfonychloride the corresponding methyl esters are prepared.
In the above example, when the sodium salts of ethanol, butanol, benzyl alcohol and phenol are used in place of sodium methoxide along with the appropriate alcohol in place of methanol, the corresponding sulfonic acid ester is prepared. A representative list of the compounds prepared is shown below.
methyl fonate ethyl 5-(p-nitrophenyl)-2 methoxyphenyl sulfonate I benzyl S-(p-nitrophenyl)-2-benzyloxyphenyl sulfonate methyl 5-(a-naphthyl) 2-isopropoxyphenyl sulfonate butyl 5-(p-dimethylaminophenyl)-2-isopropox yphenyl sulfonate phenyl S-(p-fluorophenyl)-2-isopropoxyphenyl sulfonate I methyl 5-(pdrifluoromethylphenyl) 2-methoxyphenylsulfonate methyl 5-(p-methoxyphenyl)-2-isopropoxyphenyl sulfonate ethyl 5-(omethylphenyl)-2-ethoxyphenyl sulfonate methyl 5-(p-mercaptophenyl)-2-isopropoxyphenyl sulfonate methyl 5-(4-pyridyl)-2-isopropoxyphenyl sulfonate benzyl 5-(3-pyridyl)-2-methoxyphenyl sulfonate phenyl 5 -(4-pyridyl)-2-benzyloxyphenyl sulfonate methyl 5-(2-thienyl)-2-ethoxyphenyl sulfonate ethyl 5-(3-thienyl)-2-isopropoxyphenyl sulfonate EXAMPLE ll Methyl S-(p-fluorophenyl)-2-acetoxyphenyl sulfonate A solution/suspension of I 5-(p-fluorophenyl)-2- acetoxyphenyl sulfonic acid silver salt (prepared by ad- 5-(p-fluorophenyl)-2-me'thoxyphenyl sulding an excess of silver nitrate to an aqueous solution of sulfonic acid and filtering off the precipitated salt) in a large excess of methyl iodide is stirred and refluxed for 1 hour. Silver salts are filtered off and solvent removed in vacuo leaving methyl -(p-fluorophenyl)-2-acetoxyphenyl sulfonate.
When the sulfonic acids of Examples 4 and 5 are used in place of 5-(p-fluorophenyl)-2-acetoxyphenyl sulfonic acid the corresponding methyl esters are prepared.
When ethyliodide, butyliodide, henzyliodide, phenethyl iodide and phenyl lithium are used in place of methyl iodide in the above example, the corresponding Z-acetoxy sulfonic acid ester is prepared. A representative list of the compounds prepared is shown below.
benz yl fonate methyl S-(p-nitrophenyl)-2-acetoxyphenyl sulfonate 5 (p-fluorophenyl)-2-acetoxyphenyl sulmethyl 5-(o-methylphenyl)-2-acetoxyphenyl sulfonate methyl 5-(p-methoxyphenyl)-2-acetoxyphenyl sulfonate methyl 5-(p-dimethylaminophenyl)-2-acetoxyphenyl sulfonate sulbenzyl 5-(p-fluorophenyl)-Z-hydroxyphenyl sulfonate ethyl 5-(p-methoxyphenyl)-2-hydroxyphenyl sulfonate methyl 5 a-naphthyl )-2-hydroxyphenyl sulfonate ethyl 5-styryl-2-hydroxyphenyl sulfonate methyl 5 4-pyridyl )-2-h ydroxyphenyl sulfonate phenyl 5 3 -pyridyl )-2-hydroxyphenyl sulfonate benzyl 5 2-thienyl )-2-h ydroxyphenyl sulfonate EXAMPLE l2 Sodio 5-(p-fluorophenyl)-2-hydroxy phenyl sulfonate To a solution of 0.001 mole of sodium hydroxide in 15 ml. of water is added 0.001 mole of 5-(pfluorophenyl) -2-hydroxy phenyl sulfonic acid in ml. of ethanol. The mixture is stirred, no need to heat, and evaporated in vacuo to obtain sodio S-(p-fluorophenyl)-2-hydroxy phenyl sulfonate.
When an equimolar amount of potassium hydroxide, lithium carbonate, aluminum hydroxide, sodium carbonate or calcium hydroxide are used in place of sodium hydroxide the corresponding salt is prepared.
When the 5-(p-fluorophenyl)-2-hydroxy phenyl sulfonic acid of the above procedure is replaced by any of the sulfonic acid compounds of this invention, the corresponding salt is prepared.
When two equivalents of the above bases are used in the above examples, the corresponding disalt is prepared. v
The following representative examples illustrate the interconversion or introduction of functional groups which can be accomplished at various stages of the preparation of the final products.
Ethyl S-(p-aminophenyD-Z-methoxyphenyl sulfonate A mixture of pure ethyl S-(p-nitrophenyl)-2-methoxyphenyl sulfonate (0.01 mole) in methanol-dioxane (1:1) (ca. 200 ml.) is reacted with hydrogen at room temperature (40 p.s.i.) in the presence of 10% ld/C (1.0 g.). The mixture is filtered, the cake washed well with methanol, the filtrate evaporated in vacuo, the residue chromatographed on a silica gel column using a methanol-methylene chloride system (v/v 0-30 percent methanol) as eluant to yield ethyl 5-(p-aminophenyl)- Z-methoxyphenyl sulfonate.
Ethyl 5-(p-hydroxyphenyl)-2-methoxyphenyl sulfonate A mixture of ethyl 5-(p-aminophenyl)-2-methoxyphenyl sulfonate (0.2 moles), water (600 ml.) and concentrated sulfuric acid (25 ml.) is'cooled to 10C. and a solution of sodium nitrite (0.21 mole) in a minimum of water is added gradually. When the presence of free nitrous acid is detected (starch-iodide paper), the addition is stopped and thediazotization mixture is allowed to warm to room temperature, then heated on a steam-bath until there is no more nitrogen evolution. The mixture is cooled, extracted well with chloroform, the combined chloroform layer dried, concentrated to a residue, methanol (300 ml.) added plus 0.5 ml. concentrated sulfuric acid, the mixture heated gently for several hours, the mixture concentrated in vacuo to remove most of the methanol, the residue partitioned between chloroform-dilute sodium bicarbonate solution, the chloroform layer dried, filtered and concentrated to a residue. Chromatography of the residue on a silica gel column using an ether-petroleum ether (v/v 0-100 percent ether) system as eluant yields ethyl S-(p-hydroxyphenyl)-2-methoxyphenyl sulfonate.
Methyl S-(p-methylthiophenyl)-2-isopropoxyphenyl sulfonate A mixture of methyl 2-(p-mercaptophenyl)-2- isopropoxyphenyl sulfonate (0.01 moles) in a deaerated aqueous KOH solution (0.01 mole) is treated with dimethylsulfate (0.012 mole) at room temperature over 1 hour, the mixture acidified, extracted well with ether, and the dried ether extracts chromatographed on a silica gel column using an ether-petroleum ether system (v/v O-30 percent ether) as eluant yielding methyl S-(p-methylthiophenyl) -2-isopropoxyphenyl sulfonate.
Methyl 5-(p-methylsulfinylphenyl)-2- isopropoxyphenyl sulfonate To an ice-cooled solution of methyl S-(p-methylthiophenyl)-2-isopropoxyphenyl sulfonate (0.01 mole) in methanol-acetone is added a solution of sodium metaperiodate (0.01 mole) in a minimum of water, and the mixture stirred at 0-8% C. until precipitation of sodium iodate is completed. The iodate is removed by filtration, the solvents removed in vacuo, and the Ar is phenyl containing one or more R substituents residue taken up in chloroform and ether. The comwhich may be at any position on the ring; bined organic extracts are dried, filtered and concen- R is halogen, trifluoromethyl, hydroxy, lower alkoxy, trated. Purification of the methyl S-(p-methylsulfinitro, amino, di(lower alkyl)amino, mercapto,- nylphenyl)-2-isopropoxyphenyl sulfonate is affected lower alkylthio, l0W6! alkylsulfinyl; via recrystallization or chromatography (silica gel) of 1 is M Where M is an alkali, alkaline its methyl ester. earth or aluminum metal; and
We claim: R is hydrogen, or lower alkanoyl. I
1. A compound of the formula; 2. A compound according to claim 1 where Ar is phenyl, R is halo, R, is --OH; or --OM; and R is hydrogen or lower alkanoyl.
'O s 3. The compound 5(p-fluorophenyl)-2-hydroxl l R yphenylsulfonic acid.
2 L J 4. The compound S-(p-fluorophenyl)-2-acetoxyphenylsulfonic acid. where a

Claims (3)

1. A compound of the formula: where Ar is phenyl containing one or more R substituents which may be at any position on the ring; R is halogen, trifluoromethyl, hydroxy, lower alkoxy, nitro, amino, di(lower alkyl)amino, mercapto, lower alkylthio, lower alkylsulfinyl; R1 is -OH, -OM where M is an alkali, alkaline earth or aluminum metal; and R2 is hydrogen, or lower alkanoyl.
2. A compound according to claim 1 where Ar is phenyl, R is halo, R1 is -OH; or -OM; and R2 is hydrogen or lower alkanoyl.
3. The compound 5-(p-fluorophenyl)-2-hydroxyphenylsulfonic acid.
US00836610A 1969-06-25 1969-06-25 5-arylphenyl sulfonic acids Expired - Lifetime US3714232A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83661069A 1969-06-25 1969-06-25

Publications (1)

Publication Number Publication Date
US3714232A true US3714232A (en) 1973-01-30

Family

ID=25272332

Family Applications (1)

Application Number Title Priority Date Filing Date
US00836610A Expired - Lifetime US3714232A (en) 1969-06-25 1969-06-25 5-arylphenyl sulfonic acids

Country Status (1)

Country Link
US (1) US3714232A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860636A (en) * 1972-12-06 1975-01-14 Merck & Co Inc Substituted indenyl phosphonic acids having anti-inflammatory activity
US5414121A (en) * 1990-08-03 1995-05-09 The Dow Chemical Company Adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties
US20040110954A1 (en) * 2001-03-30 2004-06-10 Palovich Michael R. Methods of synthesizing phenol-contining compounds
USRE39420E1 (en) 1996-04-05 2006-12-05 Sankyo Company, Limited 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2828334A (en) * 1953-06-08 1958-03-25 Petrolite Corp Oxypropylated derivatives of substituted phenol-sulfonic acid salts and method of making same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2828334A (en) * 1953-06-08 1958-03-25 Petrolite Corp Oxypropylated derivatives of substituted phenol-sulfonic acid salts and method of making same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860636A (en) * 1972-12-06 1975-01-14 Merck & Co Inc Substituted indenyl phosphonic acids having anti-inflammatory activity
US5414121A (en) * 1990-08-03 1995-05-09 The Dow Chemical Company Adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties
USRE39420E1 (en) 1996-04-05 2006-12-05 Sankyo Company, Limited 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses
US20040110954A1 (en) * 2001-03-30 2004-06-10 Palovich Michael R. Methods of synthesizing phenol-contining compounds
US8247423B2 (en) 2007-07-12 2012-08-21 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders

Similar Documents

Publication Publication Date Title
SU1205764A3 (en) Method of producing trisubstituted imidazole derivatives or salts thereof
US3654349A (en) Substituted indenyl acetic acids
US3058882A (en) N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
US4412992A (en) 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US3642785A (en) Indenyl-3-aliphatic amines
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
SU719498A3 (en) Method of preparing 1-nitro-9-alkylaminoalkylaminoacridines or their salts
US3714232A (en) 5-arylphenyl sulfonic acids
PT87578B (en) METHOD FOR PREPARING NEW ALKANO-SULFONANILIDA DERIVATIVES AND A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM
SU676165A3 (en) Method of obtaining 6-phenyl-s-triazolo-(4,3-a)-pyrido-(2,3-f)-(1,4)-diazepines or salts thereof
JPH0150698B2 (en)
CA1202317A (en) Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them
US3772444A (en) 5-aryl and heteroarylphenyl sulfonic acids to treat inflammation
US3691185A (en) 5-aryl and arylphenyl sulfonic acids in treating inflammation
US3506658A (en) 2-(10-methyl-2-phenoxazinyl)propionic acid
US2906757A (en) Their preparation
US3238200A (en) Oxadiazinediones
US3112337A (en) 4-halo-3-sulfamoylbenzoic acid esters
US3377351A (en) Benzamidoalkylbenzenesulfonamidopyrimidines and analogues thereof
US4492710A (en) Substituted pyrrolidinyl-benzoic acid derivatives and a process for their manufacture
GB2211187A (en) Tromethamine salt of 1-methyl-¼-oxo-alpha-(phenylcarbamoyl)-2-pyrrolepropio- nitrile
JPS5883687A (en) Novel asymmetrically substituted maleic anhydride and manufacture thereof
US3203987A (en) 4-halo-3-sulfamoylbenzamides and methods of preparing the same
US2654753A (en) 2-sulfanilamido-5-aminopyrimidine and salts thereof
US3414614A (en) Acetamidine derivatives